NCT02958462 Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
| NCT ID | NCT02958462 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Myeloid Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2017-01-16 |
| Primary Completion | 2030-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,000 participants in total. It began in 2017-01-16 with a primary completion date of 2030-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.
Eligibility Criteria
Inclusion Criteria: * Patients with idiopathic cytopenias of unclear significance (ICUS) * Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic) * Patients with clonal cytopenias of undetermined significance (CCUS) * Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders * Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc. * Low risk MDS (idiopathic dysplasia of unclear significance) * Family member of a patient with one of the above conditions * Patient at high risk or suspected of developing one of the above conditions Exclusion Criteria: * Patients under 18 years of age
Contact & Investigator
Mrinal S. Patnaik, MBBS
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT02958462 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloid Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02958462 currently recruiting?
Yes, NCT02958462 is actively recruiting participants. Contact the research team at cimpmlresearch@mayo.edu for enrollment information.
Where is the NCT02958462 trial being conducted?
This trial is being conducted at Scottsdale, United States, Jacksonville, United States, Rochester, United States.
Who is sponsoring the NCT02958462 clinical trial?
NCT02958462 is sponsored by Mayo Clinic. The principal investigator is Mrinal S. Patnaik, MBBS at Mayo Clinic. The trial plans to enroll 2,000 participants.